Skip to main content
Premium Trial:

Request an Annual Quote

Lynx, Institute for Systems Biology Study Prostate Cancer

NEW YORK, May 21-Lynx Therapeutics will collaborate with Seattle's Institute for Systems Biology to study gene expression in prostate cancer, the company said today.

 

Lynx will apply its core "Massively Parallel Signature Sequencing" technology to identify genes that are differentially expressed in this cancer, and ISB will contribute other data. Together, the two will work to develop a systems biology approach to studying the disease.

 

Prostate cancer typically progresses from a localized androgen-dependent disease to a more dangerous metastatic form, but the biological details of this transformation are not well understood. The systems biology approach, according to Lynx, may provide new insights into the mechanisms of this disease.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.